Walline Crystal C, Nichols David E, Carroll F Ivy, Barker Eric L
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
J Pharmacol Exp Ther. 2008 Jun;325(3):791-800. doi: 10.1124/jpet.108.136200. Epub 2008 Mar 19.
The human serotonin transporter (hSERT) regulates the spatial and temporal actions of serotonin (5-HT) neurotransmission by removing 5-HT from the synapse. Previous studies have identified residues in the third transmembrane helix (TMH) that may be important for substrate translocation or antagonist recognition. We identified hSERT residues in TMH III that are divergent from Drosophila SERT and used species-scanning mutagenesis to generate reciprocal mutants. Transport inhibition assays suggest that the potency of substituted amphetamines was decreased for the hSERT mutants A169D, I172M, and S174M. In addition, there was a loss of potency for several antidepressants and 3-phenyltropane analogs for the I172M mutant. These results suggest that residues in TMH III may contribute to antagonist recognition. We carried out comparative molecular field analyses using selectivity fields to directly visualize the mutation-induced effects of antagonist potency for antidepressants, 3-phenyltropane analogs, and amphetamines. The hSERT I172M selectivity field analysis for the 3-phenyltropane analogs revealed that electrostatic interactions resulted in decreased potency. The amphetamine and antidepressant selectivity field analyses reveal the observed decreases in potencies for the hSERT I172M mutant are due to a change in tertiary structure of the hSERT protein and are not due to disruption of a direct binding site. Finally, the hSERT mutant A169D displayed altered kinetics for sodium binding, indicating that this residue may lie near the putative sodium binding site. A SERT homology model developed from the Aquifex aeolicus leucine transporter structure provides a structural context for further interpreting the results of the TMH III mutations.
人类血清素转运体(hSERT)通过从突触中移除5-羟色胺(5-HT)来调节5-HT神经传递的空间和时间作用。先前的研究已经确定了第三跨膜螺旋(TMH)中的一些残基,这些残基可能对底物转运或拮抗剂识别很重要。我们确定了TMH III中与果蝇SERT不同的hSERT残基,并使用物种扫描诱变产生了相互突变体。转运抑制试验表明,对于hSERT突变体A169D、I172M和S174M,取代苯丙胺的效力降低。此外,I172M突变体对几种抗抑郁药和3-苯基托烷类似物的效力丧失。这些结果表明,TMH III中的残基可能有助于拮抗剂识别。我们使用选择性场进行了比较分子场分析,以直接可视化突变诱导的抗抑郁药、3-苯基托烷类似物和苯丙胺拮抗剂效力的影响。对3-苯基托烷类似物的hSERT I172M选择性场分析表明,静电相互作用导致效力降低。苯丙胺和抗抑郁药的选择性场分析表明,观察到的hSERT I172M突变体效力降低是由于hSERT蛋白三级结构的变化,而不是由于直接结合位点的破坏。最后,hSERT突变体A169D显示出钠结合动力学改变,表明该残基可能位于假定的钠结合位点附近。从嗜热栖热菌亮氨酸转运体结构开发的SERT同源模型为进一步解释TMH III突变的结果提供了结构背景。